Scholarlink

<p>Antibody-drug conjugates (ADCs) and T-cell-dependent bispecific antibodies (TDBs) show single-agent efficacy in relapsed/refractory (R/R) lymphomas. While coadministering therapeutics with orthogonal mechanisms of action may safely enhance efficacy, testing every potential combination regimen is infeasible in the clinic. An integrated quantitative systems pharmacology model of a CD19-targeted ADC and CD3/CD20-targeted TDBs was developed to predict combination regimen efficacy in R/R diffuse large B-cell lymphoma (DLBCL). Clinically validated models of the ADC loncastuximab tesirine and TDB mosunetuzumab were combined and extended to additional TDBs (glofitamab and epcoritamab). Virtual DLBCL populations were calibrated using monotherapy response data, and tumor volume dynamics simulated under alternate combination dosing regimens and patient scenarios. Additive antitumor effects were predicted from the fourth cycle onward, with combination efficacy insensitive to loncastuximab tesirine dose reductions or patient lymphopenias. Results of the LOTIS-7 study (NCT04970901) will soon be available to assess these predictions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月11日

查看全文
  • Yuezhe Li,
  • A. Katharina Wilkins,
  • Jimena Davis,
  • Timothy Knab,
  • Marie Toukam,
  • Joseph P. Boni,
  • Daniel C. Kirouac

摘要

Antibody-drug conjugates (ADCs) and T-cell-dependent bispecific antibodies (TDBs) show single-agent efficacy in relapsed/refractory (R/R) lymphomas. While coadministering therapeutics with orthogonal mechanisms of action may safely enhance efficacy, testing every potential combination regimen is infeasible in the clinic. An integrated quantitative systems pharmacology model of a CD19-targeted ADC and CD3/CD20-targeted TDBs was developed to predict combination regimen efficacy in R/R diffuse large B-cell lymphoma (DLBCL). Clinically validated models of the ADC loncastuximab tesirine and TDB mosunetuzumab were combined and extended to additional TDBs (glofitamab and epcoritamab). Virtual DLBCL populations were calibrated using monotherapy response data, and tumor volume dynamics simulated under alternate combination dosing regimens and patient scenarios. Additive antitumor effects were predicted from the fourth cycle onward, with combination efficacy insensitive to loncastuximab tesirine dose reductions or patient lymphopenias. Results of the LOTIS-7 study (NCT04970901) will soon be available to assess these predictions.